{"nctId":"NCT00296036","briefTitle":"Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer","startDateStruct":{"date":"2006-06"},"conditions":["Breast Cancer","Drug/Agent Toxicity by Tissue/Organ","Unspecified Adult Solid Tumor, Protocol Specific"],"count":137,"armGroups":[{"label":"Arm I (closed to accrual as of 10/24/2007)","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: pyridoxine hydrochloride","Drug: urea/lactic acid-based topical cream"]},{"label":"Arm II (closed to accrual as of 10/24/2007)","type":"EXPERIMENTAL","interventionNames":["Drug: urea/lactic acid-based topical cream","Other: placebo"]},{"label":"Arm III (closed to accrual as of 10/24/2007)","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: pyridoxine hydrochloride","Other: placebo"]},{"label":"Arm IV (closed to accrual as of 10/24/2007)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]},{"label":"Arm V","type":"EXPERIMENTAL","interventionNames":["Drug: urea/lactic acid-based topical cream"]},{"label":"Arm VI","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"pyridoxine hydrochloride","otherNames":[]},{"name":"urea/lactic acid-based topical cream","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast and/or other cancer\n* Undergoing first treatment with capecitabine as adjuvant (including neo-adjuvant) therapy OR for metastatic disease\n\n  * Receiving a dose of capecitabine either 2,000 mg/day (1,000 mg twice daily) OR 2,500 mg/day for 14 days with 4 courses of therapy at 3 week (+/- 3 days) intervals\n* Hormone-receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* No history of allergy to urea-containing cream\n* No pre-existing neuropathy ≥ grade 2\n* No other dermatologic condition, that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment\n\nPRIOR CONCURRENT THERAPY:\n\n* No other concurrent agents that function to prevent palmar-plantar erythrodysesthesia caused by capecitabine or topical agents in the hands or feet for other indications (e.g., dryness)\n* No concurrent vitamin B6 \\> 50 mg/day\n* No concurrent or planned use of over-the-counter products that contain urea or lactic acid, including any of the following:\n\n  * Aqua Care®\n  * Medicated Calamine\\^® lotion (0.3%)\n  * Coppertone\\^® Waterproof Ultra Protection Sunblock\n  * Dr. Scholl's\\^® Smooth Touch deep moisturizing cream\n  * Depicure\\^® So Smooth Cream\n  * Dove\\^® Moisturizing Cream Wash\n  * Cetaphil\\^ ®Moisturizing Cream\n  * Vaseline Intensive Care \\^ ® lotion","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar Erythrodysesthesia","description":"A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"To Evaluate the Potential Toxicity of Urea/Lactic Acid Cream","description":"Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Determine Whether the Prophylactic Use of Vitamin B6 Can Decrease the Incidence and/or Severity of Capecitabine-caused Palmar-plantar Erythrodysesthesia (HFSD).","description":"A patient self-reported hand-foot syndrome diary (HFSD) was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms were tabulated and percentages are reported.","classes":[]},{"type":"SECONDARY","title":"Evaluate the Potential Toxicity of Vitamin B6.","description":"Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report.","classes":[]},{"type":"SECONDARY","title":"Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream in Combination With Vitamin B6 Can Decrease the Incidence and/or Severity of Capecitabine Caused Palmar-plantar Erythrodysesthesia.","description":"A patient self-reported hand-foot syndrome diary (HFSD) was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms were tabulated.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":67},"commonTop":["Hand-and-foot syndrome","Diarrhea","Dehydration","Fatigue","Nausea"]}}}